Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275222 · ClinicalTrials.gov registry record · Phase 1
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT01275222: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT01275222 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 117 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01275222, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
Primary Outcome
Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.
Interventions
- DRUG RAD001
- DRUG Imatinib 600mg/day (Glevec is the brand name for imatinib)
- DRUG Imatinib 800mg/day (Glevec is the brand name for imatinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2002-11-13 |
| Est. Completion | 2008-09-03 |
| Phase | Phase 1 |
What the finished NCT01275222 record still lists
NCT01275222 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 3 interventions - of which RAD001 is the first listed.
NCT01275222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01275222 about?
NCT01275222 is a clinical study titled "Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors". This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
What is the current status of trial NCT01275222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2002-11-13. Estimated completion is 2008-09-03.
What interventions are being tested in trial NCT01275222?
The interventions under investigation include: RAD001 (DRUG), Imatinib 600mg/day (Glevec is the brand name for imatinib) (DRUG), Imatinib 800mg/day (Glevec is the brand name for imatinib) (DRUG).
Who is sponsoring clinical trial NCT01275222?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01275222's enrollment target sits among peer trials
117 499th of 2000 higher than 1,500 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI